The Effect of Pneumococcal Polysaccharide Vaccine in a Mouse Model of Allergic Rhinitis

Shin, Ji-Hyeon; Kim, Boo Young; Park, Hyang Rim; Kim, Sung Won; Kim, Soo Whan

doi:10.1177/0194599812472864

Cited by 5 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study demonstrated that intranasal pretreatment with PC suppresses nasal symptoms and allergic inflammation of the nasal mucosa in a murine model of AR. The inhibitory effects of intranasal immunization with PC on nasal symptoms are similar to those reported by previous studies, in which nasal symptoms in a murine AR model induced by sensitization with Der f were reduced by intranasal pretreatment with pneumococcal polysaccharide vaccine and pneumococcal conjugate vaccine . Furthermore, in the present study, the levels of serum IgE and eosinophil infiltration into the nasal mucosa were significantly decreased by intranasal PC pretreatment similar to the experiments using pneumococcal vaccines .…”

Section: Discussionsupporting

confidence: 90%

“…The same results were observed in the experiments using pneumococcal vaccines, although the administration of killed Spn before OVA sensitization significantly enhanced IFN‐γ production from mediastinal lymph node T cells . Furthermore, it has been reported that regulatory T cells are associated with the suppression of Th2‐type immune response by pneumococcal vaccines . Although PC is a T cell‐independent antigen and does not induce regulatory T cells, conjugation to a protein carrier such as KLH allows the involvement of T cells, indicating that intranasal administration of PC‐KLH might have induced regulatory T cells and suppressed IL‐4 production.…”

Section: Discussionmentioning

confidence: 94%

“…Some investigators have demonstrated the inhibition of allergic inflammation in animal models of asthma by intratracheal immunization with whole killed Spn or intranasal administration of pneumococcal conjugate vaccine . Kim et al and Shin et al reported that intranasal administration of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine suppressed allergen‐specific IgE production and attenuated allergic inflammation in a murine model of allergic rhinitis (AR) sensitized with Dermatophagoides farinae (Der f) . Because PC is a component of pneumococcal cell wall and polysaccharide, its presence might be associated with the suppression of allergen‐specific IgE production and allergic inflammation in pneumococcal vaccine administration.…”

Section: Introductionmentioning

confidence: 99%

“…12,13 Kim et al and Shin et al reported that intranasal administration of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine suppressed allergen-specific IgE production and attenuated allergic inflammation in a murine model of allergic rhinitis (AR) sensitized with Dermatophagoides farinae (Der f). 14,15 Because PC is a component of pneumococcal cell wall and polysaccharide, its presence might be associated with the suppression of allergen-specific IgE production and allergic inflammation in pneumococcal vaccine administration. In fact, a recent study showed that exposure of neonatal mice to PC-bearing pneumococci significantly reduced house dust mite-specific IgE production and development of airway hyper-responsiveness during adult life.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Intranasal immunization with phosphorylcholine suppresses allergic rhinitis in mice

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intranasal immunization with phosphorylcholine suppresses allergic rhinitis in mice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Children with pre-existing neurologic conditions and immune compromise were at increased risk of pH1N1-associated death after PICU admission 39. Most of the available safety data indicated that the single-dose use of peramivir in adults and pediatric outpatient populations commonly led to AEs that reportedly included diarrhea, nausea, vomiting, and neutropenia 12,61,62. Available data related to AEs of multiple-dose peramivir in critically ill patients are scarce 37…”

Section: Resultsmentioning

confidence: 99%

Safety and efficacy of peramivir for influenza treatment

Hata¹,

Akashi-Ueda²,

Takamatsu³

et al. 2014

DDDT

View full text Add to dashboard Cite

ObjectiveThis report presents a review of the efficacy and safety of peramivir, a neuraminidase inhibitor that was granted Emergency Use Authorization by the US Food and Drug Administration (FDA) from October 23, 2009 to June 23, 2010 during the 2009 H1N1 pandemic.MethodsLiterature was accessed via PubMed (January 2000–April 2014) using several search terms: peramivir; BCX-1812; RWJ 270201; H1N1, influenza; antivirals; and neuraminidase inhibitors. The peramivir manufacturers, Shionogi and Co Ltd and BioCryst Pharmaceuticals, were contacted to obtain unpublished data and information presented at recent scientific meetings. Information was obtained from the Centers for Disease Control and Prevention (CDC) and from US FDA websites. English-language and Japanese-language reports in the literature were reviewed and selected based on relevance, along with information from the CDC, US FDA, and the drug manufacturers.ResultsWe obtained eleven clinical trial reports of intravenous peramivir, two of which described comparisons with oseltamivir. Seven of nine other recently reported published studies was a dose–response study. Clinical reports of critically ill patients and pediatric patients infected with pandemic H1N1 described that early treatment significantly decreased mortality. Peramivir administered at 300 mg once daily in adult patients with influenza significantly reduces the time to alleviation of symptoms or fever compared to placebo. It is likely to be as effective as other neuraminidase inhibitors.ConclusionAlthough peramivir shows efficacy for the treatment of seasonal and pH1N1 influenza, it has not received US FDA approval. Peramivir is used safely and efficiently in hospitalized adult and pediatric patients with suspected or laboratory-confirmed influenza. Peramivir might be a beneficial alternative antiviral treatment for many patients, including those unable to receive inhaled or oral neuraminidase inhibitors, or those requiring nonintravenous drug delivery.

show abstract

The Comparation of Intraperitoneal Injection and Nasal-only Delivery Allergic Rhinitis Model Challenged With Different Allergen Concentration

Wang

Zhou

Zhu

et al. 2019

Am J Rhinol�Allergy

125

View full text Add to dashboard Cite

Background Predominantly, 2 animal models are used for allergic rhinitis (AR), which are established by intraperitoneal (IP) injection plus local challenge and nasal-only delivery. The differences between these 2 models are not fully understood. Moreover, dose–response relationship to allergens remains unclear. Methods In this study, mice were sensitized by nasal drops (without adjuvant, once daily for 9 weeks) to set up a nasal-only delivery AR model. Five different doses of ovalbumin (OVA) nasal drops were served to explore the dose–response to allergens. Allergic symptoms, serum antibodies (IgE, IgG2a, and IgG1), spleen supernatant and nasal lavage fluid (NALF) cytokines (IL-4, IL-5, and IFN-r), and infiltrated eosinophils of the nasal mucosa were observed. Results The allergic symptoms, serum antibodies, cytokines, and infiltrated eosinophils were significantly higher in the high OVA concentration compared with those of the control group. Different OVA concentrations associated with the severity of allergy. Within a certain concentration range, OVA concentration positively related to the severity of symptoms, IgE antibody level, and Th2 bias. Meanwhile, serum antibodies (IgE and IgG1) and cytokines (IL-4, IL-5 in spleen and IL-4 in NALF) were significantly higher in the classical IP injection group than in the nasal drip groups. Conclusion The IP injection model and the nasal-only delivery model are 2 typical models for AR that causes a different immune response. A positive dose–response relationship in the nasal-only delivery model is observed from 25 mg/mL to 0.025 mg/mL.

show abstract

The Effect of Pneumococcal Polysaccharide Vaccine in a Mouse Model of Allergic Rhinitis

Cited by 5 publications

References 22 publications

Intranasal immunization with phosphorylcholine suppresses allergic rhinitis in mice

Intranasal immunization with phosphorylcholine suppresses allergic rhinitis in mice

Safety and efficacy of peramivir for influenza treatment

The Comparation of Intraperitoneal Injection and Nasal-only Delivery Allergic Rhinitis Model Challenged With Different Allergen Concentration

Contact Info

Product

Resources

About